240 related articles for article (PubMed ID: 23008295)
1. Estrogen plus progestin and colorectal cancer incidence and mortality.
Simon MS; Chlebowski RT; Wactawski-Wende J; Johnson KC; Muskovitz A; Kato I; Young A; Hubbell FA; Prentice RL
J Clin Oncol; 2012 Nov; 30(32):3983-90. PubMed ID: 23008295
[TBL] [Abstract][Full Text] [Related]
2. Continuous Combined Estrogen Plus Progestin and Endometrial Cancer: The Women's Health Initiative Randomized Trial.
Chlebowski RT; Anderson GL; Sarto GE; Haque R; Runowicz CD; Aragaki AK; Thomson CA; Howard BV; Wactawski-Wende J; Chen C; Rohan TE; Simon MS; Reed SD; Manson JE
J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26668177
[TBL] [Abstract][Full Text] [Related]
3. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.
Chlebowski RT; Anderson GL; Manson JE; Schwartz AG; Wakelee H; Gass M; Rodabough RJ; Johnson KC; Wactawski-Wende J; Kotchen JM; Ockene JK; O'Sullivan MJ; Hubbell FA; Chien JW; Chen C; Stefanick ML
J Natl Cancer Inst; 2010 Sep; 102(18):1413-21. PubMed ID: 20709992
[TBL] [Abstract][Full Text] [Related]
4. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.
Chlebowski RT; Schwartz AG; Wakelee H; Anderson GL; Stefanick ML; Manson JE; Rodabough RJ; Chien JW; Wactawski-Wende J; Gass M; Kotchen JM; Johnson KC; O'Sullivan MJ; Ockene JK; Chen C; Hubbell FA;
Lancet; 2009 Oct; 374(9697):1243-51. PubMed ID: 19767090
[TBL] [Abstract][Full Text] [Related]
5. Estrogen plus progestin and colorectal cancer in postmenopausal women.
Chlebowski RT; Wactawski-Wende J; Ritenbaugh C; Hubbell FA; Ascensao J; Rodabough RJ; Rosenberg CA; Taylor VM; Harris R; Chen C; Adams-Campbell LL; White E;
N Engl J Med; 2004 Mar; 350(10):991-1004. PubMed ID: 14999111
[TBL] [Abstract][Full Text] [Related]
6. Menopausal hormone therapy and risks of melanoma and nonmelanoma skin cancers: women's health initiative randomized trials.
Tang JY; Spaunhurst KM; Chlebowski RT; Wactawski-Wende J; Keiser E; Thomas F; Anderson ML; Zeitouni NC; Larson JC; Stefanick ML
J Natl Cancer Inst; 2011 Oct; 103(19):1469-75. PubMed ID: 21878677
[TBL] [Abstract][Full Text] [Related]
7. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women.
Chlebowski RT; Anderson GL; Gass M; Lane DS; Aragaki AK; Kuller LH; Manson JE; Stefanick ML; Ockene J; Sarto GE; Johnson KC; Wactawski-Wende J; Ravdin PM; Schenken R; Hendrix SL; Rajkovic A; Rohan TE; Yasmeen S; Prentice RL;
JAMA; 2010 Oct; 304(15):1684-92. PubMed ID: 20959578
[TBL] [Abstract][Full Text] [Related]
8. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
Manson JE; Chlebowski RT; Stefanick ML; Aragaki AK; Rossouw JE; Prentice RL; Anderson G; Howard BV; Thomson CA; LaCroix AZ; Wactawski-Wende J; Jackson RD; Limacher M; Margolis KL; Wassertheil-Smoller S; Beresford SA; Cauley JA; Eaton CB; Gass M; Hsia J; Johnson KC; Kooperberg C; Kuller LH; Lewis CE; Liu S; Martin LW; Ockene JK; O'Sullivan MJ; Powell LH; Simon MS; Van Horn L; Vitolins MZ; Wallace RB
JAMA; 2013 Oct; 310(13):1353-68. PubMed ID: 24084921
[TBL] [Abstract][Full Text] [Related]
9. Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial.
McTiernan A; Martin CF; Peck JD; Aragaki AK; Chlebowski RT; Pisano ED; Wang CY; Brunner RL; Johnson KC; Manson JE; Lewis CE; Kotchen JM; Hulka BS;
J Natl Cancer Inst; 2005 Sep; 97(18):1366-76. PubMed ID: 16174858
[TBL] [Abstract][Full Text] [Related]
10. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study.
Shumaker SA; Legault C; Kuller L; Rapp SR; Thal L; Lane DS; Fillit H; Stefanick ML; Hendrix SL; Lewis CE; Masaki K; Coker LH;
JAMA; 2004 Jun; 291(24):2947-58. PubMed ID: 15213206
[TBL] [Abstract][Full Text] [Related]
11. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial.
Shumaker SA; Legault C; Rapp SR; Thal L; Wallace RB; Ockene JK; Hendrix SL; Jones BN; Assaf AR; Jackson RD; Kotchen JM; Wassertheil-Smoller S; Wactawski-Wende J;
JAMA; 2003 May; 289(20):2651-62. PubMed ID: 12771112
[TBL] [Abstract][Full Text] [Related]
12. Estrogen and colorectal cancer incidence and mortality.
Lavasani S; Chlebowski RT; Prentice RL; Kato I; Wactawski-Wende J; Johnson KC; Young A; Rodabough R; Hubbell FA; Mahinbakht A; Simon MS
Cancer; 2015 Sep; 121(18):3261-71. PubMed ID: 26036212
[TBL] [Abstract][Full Text] [Related]
13. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.
Heiss G; Wallace R; Anderson GL; Aragaki A; Beresford SA; Brzyski R; Chlebowski RT; Gass M; LaCroix A; Manson JE; Prentice RL; Rossouw J; Stefanick ML;
JAMA; 2008 Mar; 299(9):1036-45. PubMed ID: 18319414
[TBL] [Abstract][Full Text] [Related]
14. Estrogen Plus Progestin and Lung Cancer: Follow-up of the Women's Health Initiative Randomized Trial.
Chlebowski RT; Wakelee H; Pettinger M; Rohan T; Liu J; Simon M; Tindle H; Messina C; Johnson K; Schwartz A; Gass M; Wactawski-Wende J
Clin Lung Cancer; 2016 Jan; 17(1):10-7.e1. PubMed ID: 26577506
[TBL] [Abstract][Full Text] [Related]
15. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial.
Chlebowski RT; Hendrix SL; Langer RD; Stefanick ML; Gass M; Lane D; Rodabough RJ; Gilligan MA; Cyr MG; Thomson CA; Khandekar J; Petrovitch H; McTiernan A;
JAMA; 2003 Jun; 289(24):3243-53. PubMed ID: 12824205
[TBL] [Abstract][Full Text] [Related]
16. Breast Cancer After Use of Estrogen Plus Progestin and Estrogen Alone: Analyses of Data From 2 Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Rohan TE; Manson JE; Aragaki AK; Kaunitz A; Stefanick ML; Simon MS; Johnson KC; Wactawski-Wende J; O'Sullivan MJ; Adams-Campbell LL; Nassir R; Lessin LS; Prentice RL
JAMA Oncol; 2015 Jun; 1(3):296-305. PubMed ID: 26181174
[TBL] [Abstract][Full Text] [Related]
17. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group.
Hulley S; Grady D; Bush T; Furberg C; Herrington D; Riggs B; Vittinghoff E
JAMA; 1998 Aug; 280(7):605-13. PubMed ID: 9718051
[TBL] [Abstract][Full Text] [Related]
18. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial.
Rossouw JE; Anderson GL; Prentice RL; LaCroix AZ; Kooperberg C; Stefanick ML; Jackson RD; Beresford SA; Howard BV; Johnson KC; Kotchen JM; Ockene J;
JAMA; 2002 Jul; 288(3):321-33. PubMed ID: 12117397
[TBL] [Abstract][Full Text] [Related]
19. Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials.
Chlebowski RT; Anderson GL; Aragaki AK; Manson JE; Stefanick ML; Pan K; Barrington W; Kuller LH; Simon MS; Lane D; Johnson KC; Rohan TE; Gass MLS; Cauley JA; Paskett ED; Sattari M; Prentice RL
JAMA; 2020 Jul; 324(4):369-380. PubMed ID: 32721007
[TBL] [Abstract][Full Text] [Related]
20. Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study.
Chlebowski RT; Manson JE; Anderson GL; Cauley JA; Aragaki AK; Stefanick ML; Lane DS; Johnson KC; Wactawski-Wende J; Chen C; Qi L; Yasmeen S; Newcomb PA; Prentice RL
J Natl Cancer Inst; 2013 Apr; 105(8):526-35. PubMed ID: 23543779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
